Correction to: A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease (Alzheimer's Research and Therapy (2017) 9 (95) DOI: 10.1186/s13195-017-0318-y)

Susanne Ostrowitzki, Robert A. Lasser, Ernest Dorflinger, Philip Scheltens, Frederik Barkhof, Tania Nikolcheva, Elizabeth Ashford, Sylvie Retout, Carsten Hofmann, Paul Delmar, Gregory Klein, Mirjana Andjelkovic, Bruno Dubois, Mercè Boada, Kaj Blennow, Luca Santarelli, Paulo Fontoura*

*Corresponding author for this work

Research output: Contribution to journalErratum/CorrigendumAcademicpeer-review


Following publication of the original article [1], the author reported errors in the formatting of the table. The details of the errors are as follows: In Table 1, the data presented do not correspond to the row title: The education row currently contains incorrect data. The weight row currently contains the years of education. The APOE 4 genotype row currently contains the weight data. In Table 1, the data should be displayed as follows: Variable Intention-to-treat population (n = 797) Placebo (n = 266) Gantenerumab 105 mg (n = 271) Gantenerumab 225 mg (n = 260) Age, years, mean (SD) 69.5 (7.5) 70.3 (7.0) 71.3 (7.1) Education, years, mean (SD) 12.6 (4.3)12.9 (4.8) 12.1 (4.5) Weight, kg, mean (SD) 69.8 (12.9) 70.5 (13.6) 70.1 (12.5) APOE4 genotype, %a.
Original languageEnglish
Article number99
JournalAlzheimer's Research and Therapy
Issue number1
Publication statusPublished - 2018

Cite this